In this article, we are going to take a look at where Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) stands against other high growth low debt stocks to invest in now. The global financial ...

NYSE:PLX opened at $3.00 on Thursday. The business’s 50-day moving average price is $2.50 and its 200 day moving average price is $2.08. The firm has a market cap of $234.10 million, a P/E ratio ...

Amid rising threat from Russia, Pluri partners with Ukrainian blood bank to stockpile remedy for deadly radiation poisoning that uses cells grown from donated placentas The post In case of a nuclear ...

Protalix saw record revenue growth in 2024, driven by increased sales to Chiesi, Pfizer, and Brazil. The company aims to start a Phase 2 trial for PRX-115 in 2025. The Dow Jones closed lower by ...

We initiate a Strong Buy rating on PLX. This is based on the company’s stable income, profitability, and the longer-term potential of pipeline programs like PRX-115 and PRX-119. In our opinion ...

Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation company, announced today multiple presentations with the Company's selective monovalent degrader programs for SMARCA2, ...

Short interest in Protalix BioTherapeutics Inc (AMEX:PLX) increased during the last reporting period, rising from 650.64K to 979.39K. This put 1.31% of the company's publicly available shares short.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...